FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						or Sectio	n 30(n) of the	investme	nt Comp	dany Act of	1940								
Name and Address of Reporting Person* <u>Spencer David M.</u>					2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [BLCM]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
															Director Officer (sine title below)			10% Own	
(Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800				3. Date of Earliest Transaction (Month/Day/Year) 09/04/2018									X Officer (give title below) Other (specify below) Chief Technology Officer						
(Street) HOUSTON TX 77030					If Amendment, Date of Original Filed (Month/Day/Year)								6. In	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (SI	ate)	(Zip))																
			1	Table I -	Non-Deri	ivative Sec	curities A	quired	, Disp	osed of	, or Bene	ficially Ov	/ned						
2. The or occurry (months)				2. Transacti Date	Execu	Execution Date, ear) if any		3. Transaction 4. Secu Code (Instr. 8) 3, 4 an		urities Acquired (A) or Disposed Of (D d 5)			Beneficially Owned Fo		llowing Direct (D) or Indirect (I		D) or Indirect (I)	7. Nature of Indirect Beneficial	
				(Month/Day	(Monti			ode V A		Amount (A) or (D)		Price		Reported Transaction(s (Instr. 3 and 4)		(Instr. 4)		Ownership (Instr. 4)	
Common Stock					09/04/2	018		S ⁽¹⁾		10	,000	D	\$7.0413	2)	89,939			D	
				Table I		ative Secu outs, calls							ed						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expirat	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Derivative Security (Instr. 3 and 4)					9. Number of derivative Securities Beneficially Owned Following		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security				v	(A)	(D)	Date Exprisable Date		Expiration Date			Amount o Number o		Repo Trans		ted action(s)		

Explanation of Responses:

- Explanation or Responses.

 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2018.

 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.95 to \$7.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

EXHIBIT LIST: EX-24 Power of attorney

/s/ Rosemary Y. Williams, Attorney-in-Fact 09/05/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all, by these presents, that the undersigned hereby constitutes and appoints each of Richard A. Fair, Rosemary Y. Williams and Shane M. Ward, signing inc (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of Bellicum Pharmaceuticals

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute such Form 3, 6 or 5, complete and 6 or 5, com

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the l The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necess.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with I IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of August, 2018.

/s/ David Spencer, Ph.D. (Signature) David Spencer, Ph.D. (Print Name)

181526777 v1